Firsekibart
ApprovedSmall molecule
Firsekibart is one of 46 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.
2
Indications
3
Total Trials
3
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Eptanemab
UCBPhase 3
Medrol
PfizerPhase 3
Olumiant
Eli LillyPhase 3
Gazyva
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Intrarosa
Alnylam PharmaceuticalsPhase 3
Cellcept
NovartisPhase 3
Benadryl
PParkedale
Phase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tylenol
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus1 trial
Adult-Onset Still's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Firsekibart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- RRuijin Hospital